Guide on Creutzfeldt-Jakob Disease Risk Reductions
Federal Register notice: FDA makes available a draft guidance entitled “Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt Jakob Disease by Blood and Blood Components.’’ The recommendations apply to blood and blood component collection intended for transfusion or for use in further manufacturing. To view the notice, click here.